Roche’s soaring Vabysmo sales raise the stakes in ophthalmology face-off with Regeneron’s Eylea: analyst
By Andrea Park
“If Roche’s Vabysmo continues to provide promising sales figures for the foreseeable future … Roche will have put itself on track to becoming an industry leader within the ophthalmological space,” Sara Reci, a senior pharma analyst at GlobalData, said in the report. (Getty Images)